Merck & Co., Inc. (MRK)
Merck pens $2bn deal for obesity drug from China's Hansoh
Merck & Co Inc (NYSE:MRK, ETR:6MK) has sought a potential weight loss drug candidate through a deal worth up to $2 billion with China's Hansoh Pharma. US-based Merck will get exclusive rights to develop, manufacture and sell the oral obesity drug, HS-10535, globally under the agreement, it announced on Wednesday.
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance
The FDA accepts MRK's BLA for clesrovimab, its monoclonal antibody, to protect infants from RSV disease. A decision from the agency is due on June 10, 2025.
Merck to End Development of Two Cancer Candidates: Time to Sell?
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion. Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in milestone payments and royalties on sales, according to a news release.
Merck signs up to $2 bln obesity drug deal with Chinese biotech Hansoh
U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and commercialize the Chinese biotech's experimental obesity drug.
Merck Ends Development of Two Experimental Cancer Drugs
MRK's decision to discontinue the development of two cancer drugs follows a series of setbacks in multiple late-stage studies.
Merck: Buy Opportunity Backed By Growth
Merck: Buy Opportunity Backed By Growth
Merck discontinues development of 2 cancer drugs after trial failures
Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials.
CHMP Endorses Merck's Kidney Cancer Drug for Two Indications
The CHMP's opinion is based on positive results from two late-stage studies on MRK's Welireg in two indications associated with renal cell carcinoma.
Merck Has Become Very Cheap Again
Merck's shares have declined, making its dividend yield climb and valuation compress, presenting an attractive investment opportunity at current prices. Keytruda, the company's largest drug, continues to show strong revenue growth and potential for further approvals and market expansion. MRK's diverse drug portfolio, including Gardasil and Winrevair, and its robust pipeline with numerous phase II and III programs support future growth.
Merck (MRK) Ascends While Market Falls: Some Facts to Note
Merck (MRK) reachead $101.25 at the closing of the latest trading day, reflecting a +1.5% change compared to its last close.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
Merck (MRK) closed at $99.75 in the latest trading session, marking a -1.24% move from the prior day.
